P reciPitating hydrophobic injectable liquid (PHIL; MicroVention) is a newly available liquid embolic agent for endovascular use. PHIL contains a copolymer [poly(lactide co-glycolide) and poly(hydroxyethyl methacrylate)], which is suspended in dimethyl sulfoxide (DMSO). An iodine (triiodophenol) component is covalently bonded to the polymer, making it radiopaque. CE (Conformité Européenne) approval for its use in intracranial vascular malformations was obtained in July 2014. We describe our initial experience with the treatment of intracranial vascular shunts using PHIL.
nial hemorrhage. The remaining 2 patients with AVM presented with seizures. The temporal and occipital lobes were the most common locations. Three AVMs were Spetzler-Martin Grade II. 7 One patient had a diffuse AVM (Spetzler-Martin Grade V), for which embolization was performed as part of multiple staged procedures. Three AVMs were cortically located and exhibited superficial venous drainage. Prominent lenticulostriate feeders were seen in 1 patient, and a choroidal component with deep venous drainage was noted in another patient.
Among the 4 patients with DAVFs, 1 patient presented with an intracranial hemorrhage and the remaining 3 patients presented with headache, with additional orbital symptoms in 1 patient. Two DAVFs were located along the tentorium; 1 was in the right paracavernous region, and the final DAVF was located at the left transverse sigmoid junction. Two patients had Cognard Type IIa+b, 2 AVFs, and direct cortical venous drainage was noted in the other 2 patients.
One patient presented with a recurrent posttraumatic left CCF after having undergone initial coil embolization. Another patient with a left parietal pial AVF presented with intracranial hemorrhage.
Procedural Details
Informed consent was obtained from all patients or their relatives prior to embolization. All embolization procedures were performed under general anesthesia with the patient intubated, and after embolization, the patient's blood pressure was maintained as per standard protocol to prevent perfusion pressure breakthrough.
DMSO-compatible microcatheters were used for embolization in all patients. After injecting DMSO to fill the dead space of the microcatheter, PHIL was injected using a push-pause technique. Percolation of the agent to the target areas was adequate despite a proximal position of the microcatheter in 2 cases. The mean duration of injection was 60 minutes (range 30-90 minutes), and the mean volume injected was 2.8 ml. The maximum injection duration was 90 minutes in a patient with a DAVF, in whom PHIL was injected through 2 separate feeders. In the patient with a pial AVF, coils were initially deployed to reduce the flow, and PHIL was subsequently injected. Another fistula in the same patient was embolized using 90% N-butyl cyanoacrylate (NBCA) in view of high-flow fistulous communication. All procedures were carried out using 25% PHIL.
Complications
No major complications related to the PHIL injection were noted. Adequate nidal penetration was achieved in all cases. Significant reflux (> 2 cm) along the left middle meningeal artery occurred in 1 patient with a transverse sigmoid dural fistula, and the catheter became trapped. It was left in situ after repeated attempts to remove it failed. No other periprocedural complications were noted. The patients' postoperative stays were uneventful.
Outcomes
Angiographic outcome of complete or near-complete embolization was acheieved in 8 (73%) patients (Fig. 1 ). Three patients with AVM had incomplete embolization ( Fig. 2 ) due to persisting deep components (choroidal and lenticulostriate in 1 patient each, in whom 80% of the nidus was embolized). In 1 patient with a Spetzler-Martin Grade V AVM, approximately 30% embolization was done as part of a staged procedure.
Follow-Up
All but 1 patient had good clinical outcomes (modified Rankin Scale score ≤ 2) during follow-up (range 8 months to 1 year). A patient with a large AVM (Spetzler-Martin Grade V), who underwent staged treatment, presented with an intraventricular hemorrhage 6 weeks after PHIL embolization. This patient was managed conservatively. Imaging follow-up with either cross-sectional MR angiography or angiography after 6 months in the other patients with incomplete embolization showed a stable PHIL cast, with no obvious recanalization of the treated nidus. These patients were subsequently referred for stereotactic radiotherapy of the residual components. No recurrence or worsening of clinical symptoms was noted in the patients in whom complete embolization was achieved.
Discussion
We have described our initial experience with the use of PHIL for the embolization of intracranial vascular malformations and shunts, relevant features of which are summarized in Table 1 . Currently, Onyx (Medtronic) is the most widely used embolic agent for intracranial embolization. It is a nonadhesive copolymer that allows discontinuous, long injections of multiple feeders.
1 Nidal penetration is also better with Onyx than earlier liquid embolic agents.
5 PHIL is also a nonadhesive copolymer and thus retains these advantages of Onyx. Early studies on PHIL have shown favorable results in the embolization of intracranial dural fistulas 4 and recently in brain AVMs. 6 An iodine component (triiodophenol) is bound to a copolymer for radiopacity. PHIL advances into the vasculature as a block or column instead of layers and is less radiopaque, being visible only outside the microcatheter tip. However, from our experience, PHIL was optimally visible during its injection, and its cast could be clearly seen within the nidus. Furthermore, the microcatheter tip was clearly visible during the procedure, even within the PHIL cast. Formation of an initial plug was required, similar to Onyx, followed by antegrade flow into the nidus. Adequate venous penetration was obtained in all of our patients after embolization of the nidus. Layering of Onyx and the presence of tantalum within it (minimum size of tantalum is approximately 8-10 μm) precluded distal penetration of the Onyx into smaller vessels; however, studies have shown that PHIL can penetrate even into vessels smaller than 3 μm, 3 since iodine is covalently bonded to the copolymer.
PHIL is available in different concentrations (25%, 30%, and 35%) based on its viscosity; we administered the 25% concentration in all of our patients. High-flow fistulous communications were noted only in the patient with the pial AVF, and we used coils to reduce the flow before injecting PHIL. In the same patient, the other fistula was embolized using 90% NBCA. There is a lack of literature regarding the use of PHIL in high-flow fistulas, and further studies are required. However, with this case, we were able to compare the postoperative PHIL cast with the NBCA cast on CT scans. Minimal streak artifacts were associated with the PHIL cast (Fig. 3) . There are previous reports of cast migration during PHIL injection, 4 which we did not encounter in our series. However, early venous filling was noted in 2 patients (Cases 6 and 10), and injection had to be stopped. After waiting a few minutes, we resumed the injection. Since PHIL travels as a column, there is a theoretical risk of early venous filling. However, it can be easily identified on the road map as a blob rather than plexiform, which would indicate the nidus. Thus, careful fluoroscopic monitoring during injection can prevent early inadvertent embolization of the venous side. On the other hand, this property allows PHIL to be injected in suboptimal positions in patients with tortuous anatomy where the fistulous point cannot be reached. In 2 of our patients, PHIL injection was performed in a suboptimal position, and we were still able to achieve satisfactory near-complete embolization of the fistula (Fig. 4) .
Previous studies have not documented a retained microcatheter within the PHIL cast. In our series, the microcatheter could not be retrieved at the end of the procedure in a patient with a DAVF in whom embolization was performed through a middle meningeal artery feeder. However, we had allowed significant reflux (> 2 cm) of the agent and had used a nondetachable microcatheter in that patient. The microcatheter was subsequently left in situ, and the patient was started on a regimen of antiplatelet medication after the procedure. No other major complications related to the PHIL injection were noted. We were able to achieve complete or near-complete embolization in 8 (73%) of our patients. Incomplete embolizations in 3 patients were related to technical factors (deep feeders and staged embolization) unrelated to the PHIL injection. Clinical follow-up from a minimum of 8 months to 1 year revealed good outcomes in the majority of patients, with only 1 patient experiencing deterioration due to an intraventricular hemorrhage 6 weeks after embolization. Imaging follow-up over 6 months showed a stable PHIL cast in situ with no obvious recanalization of the treated portions (Fig. 5) . None of the patients in whom near-complete or complete embolization was achieved exhibited any clinical recurrence of symptoms.
Comparison of PHIL With Onyx
PHIL and DMSO come in prefilled syringes that are relatively cumbersome to use compared with other syringes. There are occasions where PHIL has precipitated within the syringes over time, which is a major drawback. The agent contains covalently bonded iodine and lacks micronized tantalum compared with Onyx. Hence, it is more homogeneous and does not require prior shaking. PHIL is less radiopaque than Onyx and is often visualized only after it exits the microcatheter tip. Hence, caution must be exercised during the initial part of embolization to avoid inadvertent early venous embolization. However, this property is distinctly advantageous during the subsequent part of the procedure, when the microcatheter tip is clearly visible even amid a dense PHIL cast. PHIL travels as a column without any layering and achieves more distal penetration of the nidus due to its homogeneous composition. Oftentimes, a PHIL injection can be performed at a suboptimal proximal position, which is advantageous in cases of tortuous vessels precluding distal access. Shorter intervals (30-60 seconds) are required during injection of PHIL than Onyx (2 minutes), which allow a greater margin for reflux (2 cm). The microcatheter could not be retrieved in only 1 patient in this series. Venous embolizations are often identified as distinct blobs and thus serve as a useful sign to stop the injection. Postembolization CT scans show fewer streak artifacts with PHIL than other embolic agents. Finally, since iodine is used as the radiopaque material PHIL and has a lower atomic number than tantalum, radiation factors can be altered for adequate visualization. This, combined with the reduced procedural time (reduced intervals between injections due to variability in percolation of PHIL), should reduce the effective radiation amount to the patient and operator. However, larger studies are required to validate this supposition.
Conclusions
We have described our initial experience with using PHIL in intracranial vascular shunts, and the immediate angiographic results appear to be favorable. The clinical follow-up of 8 months to 1 year is encouraging, with only 1 patient showing deterioration. PHIL casts appear stable, with no imaging evidence of recanalization over 6 months. Large, multicenter trials comparing the different embolic agents are needed to confirm the safety, efficacy, and durability of embolization.
